Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Tech lawsuits defined 2026 — and lawmakers want more

November 18, 2026

Old Navy and Gap face probe over ‘deceptive’ marketing claims in Canada

November 18, 2026

Ford puts onus on Ottawa ahead of Stellantis Brampton plant talks

November 18, 2026

Banking outages are ‘a matter of when, not if.’ Do you know what to do?

November 18, 2026

Health Canada approves new Eli Lilly GLP-1 pill for weight loss

November 18, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Health Canada approves new Eli Lilly GLP-1 pill for weight loss
Health

Health Canada approves new Eli Lilly GLP-1 pill for weight loss

By News RoomNovember 18, 20263 Mins Read
Health Canada approves new Eli Lilly GLP-1 pill for weight loss
Share
Facebook Twitter LinkedIn Pinterest Email

Health Canada has authorized a new GLP-1 medication for weight loss that is a pill taken every day, rather than weekly injections.

Eli Lilly’s Foundayo is approved for adults with obesity as well as those who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea.

In addition to promoting and maintaining weight loss, the pill is also approved to help treat Type 2 diabetes.

Eli Lilly also makes the injectable drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. Tirzepatide acts on two receptors associated with insulin production and hunger: GLP-1 and GIP.

Competitor Novo Nordisk manufactures injectables Ozempic and Wegovy, which contain the active ingredient semaglutide. Semaglutide acts on GLP-1 receptors. Several other companies make generic semaglutide sold in Canada.

The class of drugs known as GLP-1s have revolutionized weight-loss treatment and experts say some patients may prefer to take a pill rather than an injection.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

There is another GLP-1 pill — Novo Nordisk’s Rybelsus — already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.

The active ingredient in Foundayo is orforglipron, a non-peptide GLP-1 receptor agonist.

Because it’s a smaller molecule than peptides semaglutide and tirzepatide, orforglipron can be taken orally and absorbed without being broken down by the digestive system, said Dr. Ehud Ur, an endocrinologist in Vancouver who is not associated with either Eli Lilly or Novo Nordisk.

“It seems to be just as good as if not better” for weight loss as semaglutide and tirzepatide, he said.

The most common side effects of GLP-1 medications — both injectable and oral — include gastrointestinal issues, such as nausea or vomiting.


Ur said whether he would prescribe Foundayo depends on the patient, partly because he is still waiting for clinical trial results on whether or not orforglipron has a cardiovascular benefit like semaglutide and tirzepatide do.

Foundayo received Health Canada authorization on Nov. 13. Eli Lilly spokesperson Ethan Pigott said the company expects the pills to be available in pharmacies in January.

There may soon be a second GLP-1 weight-loss pill option in Canada: competitor Novo Nordisk’s Wegovy pill, which is still awaiting Health Canada approval.

Both Foundayo and the Wegovy pill are approved and available in the U.S.

Even though Wegovy is made of the large peptide molecule semaglutide, Novo Nordisk is able to manufacture it in pill form by adding an ingredient called salcaprozate sodium to protect it from being broken down by digestive enzymes.

Once the pill is swallowed, salcaprozate sodium, or SNAC, temporarily makes the area around it less acidic and helps it pass through the stomach lining into the bloodstream, Novo Nordisk spokesperson Kate Hanna said in an email on Wednesday.

&copy 2026 The Canadian Press

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Neffy nasal spray for severe allergies now available without prescription

FDA to require vision loss warning on GLP-1 drug labels

Police investigate after 30 California marathon runners seek medical care

Intimate partner violence up 15% over 8 years in Canada, StatCan says

Stopping GLP-1 drugs could increase heart attack risk for some, study says

Beer recall hits 2 more Canadian products, bringing total to 31

U.S., Mexico both lose their measles elimination statuses: officials

GMA’s Gio Benitez shares ‘silent killer’ coronary artery disease diagnosis

PHAC finds no evidence of mystery brain disease in New Brunswick, says patients still need answers

Editors Picks

Old Navy and Gap face probe over ‘deceptive’ marketing claims in Canada

November 18, 2026

Ford puts onus on Ottawa ahead of Stellantis Brampton plant talks

November 18, 2026

Banking outages are ‘a matter of when, not if.’ Do you know what to do?

November 18, 2026

Health Canada approves new Eli Lilly GLP-1 pill for weight loss

November 18, 2026

Latest News

Avril Lavigne announces birth of 1st child: ‘Princess has arrived’

November 18, 2026

Instagram now lets you edit your stories after you post them

November 18, 2026

Driver ticketed after transport truck gets stuck under Fredericton bridge

November 18, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version